Paper4135597
Characteristics of an established cell line of retinoblastoma.
Reid TW and 7 others. J Natl Cancer Inst, 1974. Cited by 370 papers, by iCite.
Cite this record
ConductScience Library. Characteristics of an established cell line of retinoblastoma. Papers, record 4135597. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/4135597
- Cell line
- Y-7939 papers
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Connected records1
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Cell lines1
Source Cell lines
Topics17
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Cell Line | Major topic |
| Retinoblastoma | Major topic |
| Cell Division | |
| Cell Membrane | |
| Child, Preschool | |
| Chromosomes | |
| Culture Techniques | |
| Female | |
| Humans | |
| Inclusion Bodies | |
| Karyotyping | |
| Microscopy, Electron | |
| Microtubules | |
| Oncogenic Viruses | |
| RNA Viruses | |
| RNA-Directed DNA Polymerase | |
| Templates, Genetic |
Source PubMed
Cited by106
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 370 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41098871 | High expression of the eukaryotic initiation factors eIF4a and eIF4e in retinoblastoma. | Contemp Oncol (Pozn) | 2025 | https://conductscience.org/library/papers/41098871 | PubMed |
| 40170180 | A review of the 661W cell line as a tool to facilitate treatment development for retinal diseases. | Cell Biosci | 2025 | https://conductscience.org/library/papers/40170180 | PubMed |
| 39731391 | Impact of Race on the Outcomes of Retinoblastoma Treated With Primary Enucleation: A Global Study of 1426 Patients. | Clin Exp Ophthalmol | 2025 | https://conductscience.org/library/papers/39731391 | PubMed |
| 39695086 | In vitro model of retinoblastoma derived tumor and stromal cells for tumor microenvironment (TME) studies. | Cell Death Dis | 2024 | https://conductscience.org/library/papers/39695086 | PubMed |
| 39620144 | Evaluation of mesenchymal stem cells as an in vitro model for inherited retinal diseases. | Front Cell Dev Biol | 2024 | https://conductscience.org/library/papers/39620144 | PubMed |
| 39000021 | Histone Deacetylases in Retinoblastoma. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/39000021 | PubMed |
| 38730608 | Gastric Inhibitory Polypeptide Receptor (GIPR) Overexpression Reduces the Tumorigenic Potential of Retinoblastoma Cells. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/38730608 | PubMed |
| 38674157 | Role of Protein Tyrosine Phosphatase Receptor Type E (PTPRE) in Chemoresistant Retinoblastoma. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/38674157 | PubMed |
| 38447574 | In vivo CRISPR screening directly targeting testicular cells. | Cell Genom | 2024 | https://conductscience.org/library/papers/38447574 | PubMed |
| 38217258 | New retinoblastoma (RB) drug delivery approaches: anti-tumor effect of atrial natriuretic peptide (ANP)-conjugated hyaluronic-acid-coated gold nanoparticles for intraocular treatment of chemoresistant RB. | Mol Oncol | 2024 | https://conductscience.org/library/papers/38217258 | PubMed |
| 37606819 | Inhibition of high level E2F in a RB1 proficient MYCN overexpressing chicken retinoblastoma model normalizes neoplastic behaviour. | Cell Oncol (Dordr) | 2024 | https://conductscience.org/library/papers/37606819 | PubMed |
| 37340597 | Translational screening platform to evaluate chemotherapy in combination with focal therapy for retinoblastoma. | Cancer Sci | 2023 | https://conductscience.org/library/papers/37340597 | PubMed |
| 36993823 | Tumor Suppressor Role of INPP4B in Chemoresistant Retinoblastoma. | J Oncol | 2023 | https://conductscience.org/library/papers/36993823 | PubMed |
| 36293469 | ADAM10 and ADAM17-Novel Players in Retinoblastoma Carcinogenesis. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/36293469 | PubMed |
| 36034735 | Review: New horizons in retinoblastoma treatment: an updated review article. | Mol Vis | 2022 | https://conductscience.org/library/papers/36034735 | PubMed |
| 35873807 | In vitro Model Systems for Studies Into Retinal Neuroprotection. | Front Neurosci | 2022 | https://conductscience.org/library/papers/35873807 | PubMed |
| 35654783 | Induction of autophagy-dependent ferroptosis to eliminate drug-tolerant human retinoblastoma cells. | Cell Death Dis | 2022 | https://conductscience.org/library/papers/35654783 | PubMed |
| 35314658 | Retinoblastoma Cell Growth In Vitro and Tumor Formation In Ovo-Influence of Different Culture Conditions. | Methods Protoc | 2022 | https://conductscience.org/library/papers/35314658 | PubMed |
| 34930522 | In silico-labeled ghost cytometry. | Elife | 2021 | https://conductscience.org/library/papers/34930522 | PubMed |
| 34491442 | T-type calcium channels as therapeutic targets for treating "giant" retinoblastoma cancer cells. | Pflugers Arch | 2021 | https://conductscience.org/library/papers/34491442 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/4135597
GET https://conductscience.org/api/papers/v1/4135597/cited_by?page=2